License Agreements - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended				3 Months Ended		6 Months Ended
	Jun. 28, 2022	Dec. 31, 2019	Feb. 28, 2019	Sep. 30, 2018	Dec. 31, 2016	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Research And Development Arrangement Contract To Perform For Others [Line Items]
Revenue						$ 0	$ 9,417	$ 0	$ 14,068
MIT
Research And Development Arrangement Contract To Perform For Others [Line Items]
Description of future development obligations								The Company’s future development obligations are: (i) to commence a Phase 3 clinical trial for such Licensed Product within five years of the IND filing for such product, (ii) to file a New Drug Application or equivalent with the U.S. Food and Drug Administration (FDA) or comparable European regulatory agency for such Licensed Product within nine years of the IND filing for such Licensed Product, and (iii) to make a first commercial sale of such Licensed Product within 11 years of the IND filing for such Licensed Product.
License fee payment					$ 50
Percentage of shares of common stock issued					5.00%
Description of conditions to terminate license agreement								The Company has the right to terminate for any reason upon a 3-month prior written notice. MIT shall have the right to terminate if the Company ceases to carry on any business related to the MIT License Agreement. MIT may terminate the MIT License Agreement for the Company’s material breach uncured within ninety (90) days (or thirty (30) days in the case of nonpayment). MIT may also terminate the MIT License Agreement if the Company or its affiliates commence any action against MIT to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or non-infringed (a patent challenge), or if the Company's sublicensee commences such actions and the Company does not terminate such sublicense within thirty (30) days after MIT’s demand. MIT has the right to increase all payments due, instead of terminating the MIT License Agreement in the case of a patent challenge.
Right to terminate agreement upon prior written notice					3 months
Right to terminate agreement if breach remains uncured					90 days
Right to terminate agreement incase of nonpayment					30 days
MIT | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments					$ 2,900
CALIBR
Research And Development Arrangement Contract To Perform For Others [Line Items]
License fee payment				$ 1,000
Milestone payments				$ 26,000
Description of conditions to terminate license agreement								The Company may also elect to terminate its license to one or more licensed patents in any or all jurisdictions by giving ninety (90) days’ prior written notice to CALIBR. CALIBR may terminate the CALIBR License Agreement for material breach uncured within thirty (30) days. CALIBR has the right to terminate or reduce the license to a non-exclusive license if the Company fails to use diligent efforts to develop and commercially exploit CALIBR Licensed Products.
Right to terminate agreement if breach remains uncured				30 days
Percentage of Royalty on Sublicense Revenue				50.00%
Right to terminate licensed patents upon prior written notice				90 days
MEE
Research And Development Arrangement Contract To Perform For Others [Line Items]
License fee payment			$ 20
Description of conditions to terminate license agreement								The Company has the right to terminate the MEE License Agreement at will by giving thirty (30) business days advance written notice to MEE. MEE has the right to terminate the MEE License Agreement if the Company fails to make any payment due within thirty (30) business days
Right to terminate agreement upon prior written notice			30 days
Right to terminate agreement if breach remains uncured			60 days
Right to terminate agreement incase of nonpayment			30 days
Right to terminate agreement upon prior written notice if insolvent			45 days
MEE | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments			$ 350
Annual License Fee Per Share								$ 7.5
MEE | Minimum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Annual License Fee Per Share								5
Royalty Expense Per Share								$ 15
Cambridge
Research And Development Arrangement Contract To Perform For Others [Line Items]
License fee payment		$ 50
Description of conditions to terminate license agreement								The Company has the right to terminate for any reason upon 90 days’ prior to written notice. Each party has the right to terminate immediately if the other party ceases to carry on its business. Either party may also terminate the Cambridge License for material breach if such breach remains uncured for 30 days. Cambridge may also terminate the Cambridge License if the Company fails to diligently develop and commercially exploit at least one Cambridge Licensed Product or the Company or its affiliates or sub-licenses commence any action against Cambridge to declare or render any claim of the licensed patent rights invalid, unpatentable, unenforceable, or not infringed. On June 28, 2022, the Company sent Cambridge a notice stating that the Company would be terminating the Cambridge License in 90 days' time. The Company is not subject to any payments or costs as a result of this termination.
Right to terminate agreement upon prior written notice		90 days
Right to terminate agreement if breach remains uncured		30 days
Annual license fee		$ 50
Termination Of cambridge license	90 days
Cambridge | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments		$ 10,500
Patent License Agreement | MIT
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement entered date					2016-12
Patent License Agreement | CALIBR
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement entered date				2018-09
Patent License Agreement | Cambridge
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement entered date		2019-12
Non-Exclusive Patent License Agreement | MEE
Research And Development Arrangement Contract To Perform For Others [Line Items]
License agreement entered date			2019-02